In $1.36B biobuck deal with GSK, Mer­sana touts 'biggest pre­clin­i­cal ADC deal ever'

Days af­ter En­her­tu reeled in an­oth­er FDA nod, with the first-ever green light for HER2-low breast can­cer, an­oth­er an­ti­body drug con­ju­gate biotech claims it has se­cured the largest pre­clin­i­cal ADC pact to date for a sin­gle as­set.

As­traZeneca and Dai­ichi Sankyo made waves with their near­ly $7 bil­lion col­lab­o­ra­tion back in spring 2019, but at that point, En­her­tu was al­ready near­ing the FDA’s doors with clin­i­cal da­ta. The lat­est ADC tie-up to en­ter the bio­phar­ma fray cen­ters around a pre­clin­i­cal as­set, Mer­sana Ther­a­peu­tics’ XMT-2056.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER